Evidence map›Paper›PMID 35871223›Full record

ArticleNature communications2022

Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment.

Moataz Reda, Worapol Ngamcherdtrakul, Molly A Nelson, Natnaree Siriwon, Ruijie Wang, Husam Y Zaidan, Daniel S Bejan, Sherif Reda, Ngoc Ha Hoang, Noah A Crumrine and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 5 pooled it
18.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 5 syntheses or guidelines pooled it, 182 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Nanoparticles Bounded to Interfering RNAs as a Therapy for Pancreatic Cancer: A Systematic Review.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Pooled it
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Antibody-Empowered Nanomedicine for Precise Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  17. Article
  18. Review
  19. Article
  20. Review

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Moataz RedaPDX Pharmaceuticals, Inc., Portland, OR, USA.
Worapol NgamcherdtrakulPDX Pharmaceuticals, Inc., Portland, OR, USA.
Molly A NelsonPDX Pharmaceuticals, Inc., Portland, OR, USA.
Natnaree SiriwonDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, OR, USA.
Ruijie WangPDX Pharmaceuticals, Inc., Portland, OR, USA.
Husam Y ZaidanPDX Pharmaceuticals, Inc., Portland, OR, USA.
Daniel S BejanPDX Pharmaceuticals, Inc., Portland, OR, USA.
Sherif RedaPDX Pharmaceuticals, Inc., Portland, OR, USA.
Ngoc Ha HoangDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, OR, USA.
Noah A CrumrinePDX Pharmaceuticals, Inc., Portland, OR, USA.
Justin P C RehwaldtPDX Pharmaceuticals, Inc., Portland, OR, USA.
Akash BindalDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, OR, USA.ORCID 0000-0002-9834-6979
Gordon B MillsDepartment of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, OR, USA.ORCID 0000-0002-0144-9614
Joe W GrayDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, OR, USA.ORCID 0000-0001-9225-6756
Wassana YantaseePDX Pharmaceuticals, Inc., Portland, OR, USA. yantasee@ohsu.edu.ORCID 0000-0002-0989-363X
Oregon Health & Science University · USPDX Pharmaceuticals (United States) · US

Funding

Novel Nano-immunotherapy for Treatment of Non-small Cell Lung CancerR44CA265751 · NCI · PDX PHARMACEUTICALS, INC. · PI NGAMCHERDTRAKUL, WORAPOL, YANTASEE, WASSANA · 2021 to 2024
$2.2M
In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune ResponseR44CA265752 · NCI · PDX PHARMACEUTICALS, INC. · PI NGAMCHERDTRAKUL, WORAPOL, YANTASEE, WASSANA · 2021 to 2022
$2.0M
Supplement grant for R44CA217534: Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancerR44CA217534 · NCI · PDX PHARMACEUTICALS, INC. · PI GRAY, JOE W., NGAMCHERDTRAKUL, WORAPOL · 2017 to 2019
$1.7M
Development of topical formulation of siRNA-nanoparticle for treating skin diseasesR43TR001906 · NCATS · PDX PHARMACEUTICALS, INC. · PI NGAMCHERDTRAKUL, WORAPOL, YANTASEE, WASSANA · 2017 to 2017
$325k
NCATS NIH HHS R43 TR001906NCI NIH HHS R44 CA217534NCI NIH HHS R44 CA265751NCI NIH HHS R44 CA265752
6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a minority of NSCLC patients respond to ICIs, highlighting the need for superior immunotherapy. Herein, we report on a nanoparticle-based immunotherapy termed ARAC (Antigen Release Agent and Checkpoint Inhibitor) designed to enhance the efficacy of PD-L1 inhibitor. ARAC is a nanoparticle co-delivering PLK1 inhibitor (volasertib) and PD-L1 antibody. PLK1 is a key mitotic kinase that is overexpressed in various cancers including NSCLC and drives cancer growth. Inhibition of PLK1 selectively kills cancer cells and upregulates PD-L1 expression in surviving cancer cells thereby providing opportunity for ARAC targeted delivery in a feedforward manner. ARAC reduces effective doses of volasertib and PD-L1 antibody by 5-fold in a metastatic lung tumor model (LLC-JSP) and the effect is mainly mediated by CD8+ T cells. ARAC also shows efficacy in another lung tumor model (KLN-205), which does not respond to CTLA-4 and PD-1 inhibitor combination. This study highlights a rational combination strategy to augment existing therapies by utilizing our nanoparticle platform that can load multiple cargo types at once.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsNanoparticlesB7-H1 AntigenHumansImmunotherapyProgrammed Cell Death 1 ReceptorB7-H1 AntigenProgrammed Cell Death 1 Receptor

Identifiers

PMID35871223
PMCPMC9308817
OpenAlexW4286742004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.